Page 34 - Read Online
P. 34

Agresti et al. J Transl Genet Genom 2018;2:9  I  http://dx.doi.org/10.20517/jtgg.2018.05                                               Page 9 of 11

               when developing a gene therapy vector. Future directions surrounding research for these diseases should
               focus on developing a therapeutic vector that is capable of answering the aforementioned questions relating
               to: overcoming cellular and mitochondrial barriers, establish long-term (if not permanent) correction, and
               exhibiting a low (to negative) immunogenicity profile in patients.


               DECLARATIONS
               Acknowledgments
               The authors take special acknowledgment to Ueli Gubler, Ph.D. for his scientific guidance and expertise
               regarding the subject matter.


               Authors’ contributions
               Concept and design: Agresti CA, Tolias P
               Data acquisition and analysis: Agresti CA, Halkiadakis PN
               Manuscript preparation: Agresti CA, Halkiadakis PN, Tolias P
               Critical revision and finalizing of the manuscript: Agresti CA, Tolias P


               Availability of data and materials
               Not applicable.


               Financial support and sponsorship
               None.

               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2018.


               REFERENCES
               1.   Sagan L. On the origin of mitosing cells. J Theor Biol 1967;14:255-74.
               2.   Renard P, Michel S, Rommelaere G, Arnould T. Mammalian mitochodrial genetics, genomics and turnover. In: Lou PH, Petersen N,
                   editors. Cellular Bioenergetics in Health and Diseases: New Perspectives in Mitochondrial Biology. Kerala, India: Research Signpost;
                   2012. p.1-83.
               3.   Margulis L. Origin of Eukaryotic Cells. New Haven and London: Yale University Press;1970.
               4.   Cohen B. Introduction: Mitochondrial Medicine. In: Saneto RP, Parikh S, Cohen BH, editors. Mitochondrial Case Studies: Underlying
                   Mechanisms and Diagnosis. Elsevier; 2016. p.1-9.
               5.   Robin ED, Wong R. Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. J Cell Physiol
                   1988;136:507-13.
               6.   Iwasa J, Marshall M. Karp’s Cell and Molecular Biology. 8th ed. John Wiley & Sons, Inc.; 2016. p.168-97.
               7.   Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science 2012;337:1062-5.
               8.   Westrate LM, Drocco JA, Martin KR, Hlavacek WS, MacKeigan JP. Mitochondrial morphological features are associated with fission
                   and fusion events. PLoS One 2014;9:e95265.
               9.   Raulfs EC, O’Carroll IP, Dos Santos PC, Unciuleac MC, Dean DR. In vivo iron-sulfur cluster formation. Proc Natl Acad Sci U S A
                   2008;105:8591-6.
               10.  Schulz H. Beta oxidation of fatty acids. Biochim Biophys Acta 1991;1081:109-20.
   29   30   31   32   33   34   35   36   37   38   39